Policy & Regulation
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Tuesday that the European Commission has approved Cenrifki (tolebrutinib) for the treatment of second...
Japan approves Wayrilz for immune thrombocytopenia treatment
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that Japan's Ministry of Health, Labour and Welfare has granted marketing and manufactu...
Nura Bio completes USD73.8m Series B financing, advances clinical-stage SARM1 inhibitor programmes
23 June 2026 - Nura Bio Inc, a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, announced on Monday that it has completed a USD73.8m Series B financing. Th...
Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes
23 June 2026 - Clinical-stage oncology company Oxford BioTherapeutics (OBT) on Monday announced two new clinical milestones with Boehringer Ingelheim-partnered programmes, BI 3820768 (OB33) and obrixt...
Sanofi appoints new global head of Research & Development Pharma
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday the appointment of Paulo Fontoura, MD, PhD, FAAN, as executive vice president, global head of...
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer
22 June 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering the u...